HOSPITAL PROFILE
Sun Yat-sen University Cancer Center: gastrointestinal cancer, nasopharyngeal cancer and specialist evidence
Sun Yat-sen University Cancer Center (中山大学肿瘤防治中心, SYSUCC) in Guangzhou is worth examining through its disease-specific oncology teams. Medical oncology and nasopharyngeal cancer provide two useful examples, with identifiable experts and publications that readers can check internationally.
A cancer centre with several distinct specialties
SYSUCC’s official directory separates medical oncology, radiation oncology, nasopharyngeal carcinoma, surgery, pathology and molecular diagnosis, among other departments. That structure matters: a cancer second opinion may involve different expertise depending on the question.
A review of a proposed drug plan is not the same task as re-reading pathology material or assessing a radiotherapy plan. Ask which specialty will examine the particular records and which clinician will issue the written opinion.
Sources: [1]
Xu Ruihua (徐瑞华): gastrointestinal medical oncology
Xu Ruihua’s official profile identifies Medical Oncology and a focus on gastrointestinal cancers. This provides a specific starting point for researching a specialist whose interests relate to an existing gastrointestinal cancer diagnosis or proposed systemic-treatment plan.
A 2023 Cancer Cell publication about chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma lists Rui-Hua Xu with a SYSUCC Medical Oncology affiliation. The disease, author and institution can be independently checked in the NCBI record. This is evidence of relevant research involvement, not a claim that the paper determines an individual patient’s treatment.
Nasopharyngeal cancer: a visible disease-specific programme
The hospital’s radiation-oncology page lists a head-and-neck/nasopharynx section and names Jun Ma among its specialists. It describes clinical practice alongside radiation physics, treatment and nursing divisions. This gives an overseas reader a more concrete picture than a general claim that the hospital treats cancer.
The page also carries undated volume and equipment counts. We do not present those as verified 2026 totals or repeat its comparative superlatives as an independent ranking. The named section and the published research offer clearer, traceable evidence.
Sources: [4]
Ma Jun (马骏; indexed as Jun Ma): internationally searchable research
Ma’s current official profile identifies him as a professor of Radiation Oncology with a focus on nasopharyngeal carcinoma. It records a 2000–2002 postdoctoral fellowship at the University of Texas MD Anderson Cancer Center and participation in the CSCO–ASCO nasopharyngeal cancer guideline committee. These are internationally identifiable professional connections, distinct from a claim of US medical licensure.
A 2019 New England Journal of Medicine paper on induction chemotherapy for nasopharyngeal carcinoma lists Jun Ma and SYSUCC’s Radiation Oncology affiliation. PubMed identifies the study as a multicentre randomized phase 3 trial comparing treatment sequences.
This is a concrete example of the team contributing clinical evidence to an international journal. It does not mean every nasopharyngeal cancer case requires the study’s regimen, nor does authorship establish current booking availability. Keeping the Chinese name, English name, disease and institution together helps avoid confusion with similarly named researchers.
What is the practical advantage for a second-opinion enquiry?
Disease-specific teams and identifiable clinical research make it possible to ask a focused question of a relevant specialist. For example, an existing gastrointestinal cancer plan and a nasopharyngeal radiotherapy question should not be treated as interchangeable requests.
Begin with the diagnosis already established, the proposed plan and the main uncertainty you want reviewed. The provider then decides whether the records are sufficient and whether any additional specialist or original-material review is required.
Written review and language preparation
SYSUCC’s international patient guide describes document and local registration requirements for its published patient route, including Chinese-language medical documents. Those requirements should not be generalized into a guaranteed overseas remote service.
China Heal Plus focuses on coordinating written second opinions. We separately confirm case acceptance, the reviewing professional, required records, any translation and the report scope. The named doctors here are public examples of expertise, not confirmed partners or promised reviewers.
Sources: [6]
Sources and data notes
- SYSUCC: official medical department directory
Primary institutional department list; specialty presence does not establish overseas remote acceptance. Checked 7 October 2026.
- SYSUCC: Xu Ruihua official profile
Official gastrointestinal oncology interests checked 7 October 2026. This is background expertise information, not confirmed appointment availability.
- PubMed: esophageal cancer classification study, PMID 37059106
Cancer Cell, 2023. Author and Medical Oncology affiliation checked earlier today through official NCBI EFetch; research involvement is not a personal treatment recommendation. Checked 7 October 2026.
- SYSUCC: Radiation Oncology department and specialists
Official department description read this round; undated scale/equipment figures are not used as current counts. Checked 7 October 2026.
- PubMed: nasopharyngeal cancer phase 3 trial, PMID 31150573
New England Journal of Medicine, 2019. Trial design, Jun Ma authorship and SYSUCC Radiation Oncology affiliation checked; no current appointment implication. Checked 7 October 2026.
- SYSUCC: international patient information
Published visit and document requirements. This guide is not evidence that every overseas remote request will be accepted. Checked 7 October 2026.
- SYSUCC: Jun Ma official expert profile
Current official clinical interests, 2000–2002 postdoctoral training and CSCO–ASCO guideline role. Institutional biography, not independent confirmation of foreign licensure; checked 7 October 2026.
Prepared by China Heal Plus to explain healthcare resources and service choices. This is general information from the linked sources, not an individual medical assessment. Sources are not endorsements of our service.